Inflammatory response in the anterior chamber after implantation of an angle-supported lens in phakic myopic eyes.
Suphi TaneriSaskia OehlerCarsten HeinzPublished in: Journal of ophthalmology (2014)
Purpose. To evaluate the inflammatory reaction after implantation of an angle-supported foldable acrylic anterior chamber IOL for myopia correction over time. Methods. Adult individuals seeking vision correction with stable myopia >7.0 D were included. Exclusion criteria are anterior chamber depth <2.8 mm, insufficient endothelial cell density, other preexisting ocular conditions, and prior eye surgery. Laser flare photometry and slitlamp examination were performed before and up to 1 year after implantation of an AcrySof Cachet IOL (Alcon Laboratories, Forth Worth, TX, USA). Postoperative treatment comprised antibiotic eye-drops for 5 days and nonsteroidal anti-inflammatory eye-drops (NSAIDs) for 4 weeks. Results. Average laser flare values of 15 consecutive eyes of 15 patients were 8.3 ± 9.7 preoperatively and 19.0 ± 24.2 (1 day), 24.0 ± 27.5 (1 week), 17.6 ± 13.4 (1 month), 14.9 ± 15.4 (3 months), and 10.0 ± 7.0 (1 year) photon counts/ms after implantation, respectively. Slitlamp examination yielded 0 or 1+ cells (SUN classification) in every one eye throughout the follow-up period. Conclusion. Results indicate a low maximum inflammatory response and a quick recovery to a long-term safe level. The use of NSAIDs seems sufficient in routine cases, thus avoiding potential drawbacks of using corticoids.
Keyphrases
- inflammatory response
- optical coherence tomography
- end stage renal disease
- lipopolysaccharide induced
- anti inflammatory
- ejection fraction
- endothelial cells
- induced apoptosis
- multiple sclerosis
- chronic kidney disease
- lps induced
- optic nerve
- minimally invasive
- machine learning
- deep learning
- prognostic factors
- mental health
- patients undergoing
- acute coronary syndrome
- clinical trial
- ms ms
- cell cycle arrest
- atrial fibrillation
- immune response
- randomized controlled trial
- patient reported outcomes
- coronary artery disease
- cell proliferation
- high speed
- anti inflammatory drugs
- cell death
- climate change
- smoking cessation
- study protocol
- percutaneous coronary intervention
- gestational age
- placebo controlled
- replacement therapy
- vascular endothelial growth factor